Targeting these metabolic pathways (such as GLS1, ARG1, PHGDH, IDO1, etc.)may restore the function of immune cells, inhibit tumor progression, and provide new strategies for the treatment of cholangiocarcinoma. This evidence concerns the gene GLS and cholangiocarcinoma.